产品
编 号：F027011
分子式：C23H43N3O5
分子量：441.6
分子式：C23H43N3O5
分子量：441.6
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
100mg
480
In-stock
500mg
1440
In-stock
结构图
CAS No: 107133-36-8
产品详情
生物活性：
Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NF-κB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure.
体内研究：
Perindopril erbumine (0.1 mg/kg，灌胃，一次一次，连续 5 天) 对 LPS 诱导的大鼠神经炎症具有保护作用。Perindopril erbumine (0.42 mg/kg ，口服，一次一次，连续 4 周) 联合黄芪丹参汤 (4.7 g/kg，口服，一次一次，连续 4 周) 减轻 adenine(HY-B0152) 诱导的大鼠慢性肾脏病 (CKD)。Perindopril erbumine (0.4-1.5 mg/kg，口服，每天 1 次，持续 4-24 周) 对自发性高血压大鼠 (SHR) 的血压有持续性影响。Animal Model:Adenine-induced chronic kidney disease rats
Dosage:0.1 mg/kg
Administration:Oral gavage (p.o.)
Result:Abolished the LPS-induced astroglial and microglial activation.Attenuated LPS-induced TNF-α production.Prevented LPS-induced nuclear translocation of NF-кB.Prevented the AT1R up-regulation and the LPS-induced decrease in the expression of PP2A.
Animal Model:Chronic kidney disease rats
Dosage:0.42 mg/kg
Administration:Oral
Result:Obviously reduced serum creatinine (Scr) and blood urea nitrogen (BUN) levels.Displayed a marked reduction of tubulointerstitial fibrosis.Exhibited more inhibitory effect on Col-IV expression and a exceed effect of raising OPA-1 expression.Significantly increased Sirtuin3 expression.Prevented mitochondrial fragmentation.
体外研究：
Perindopril erbumine (1 μM, 24 h) 改善 LPS (HY-D1056) 诱导的大鼠星形细胞瘤细胞系 (C6) 和小鼠小胶质细胞系(BV2) 中 AT2R 表达的减少和胶质增生。Perindopril erbumine (1 μM, 24 h) 抑制LPS (HY-D1056) 诱导的大鼠星形细胞瘤细胞系 (C6) 和小鼠小胶质细胞系(BV2)中 IκBα 降解，NF-кB 核转位和 STAT3 活化。Perindopril erbumine (1 μM, 24 h) 改善LPS (HY-D1056) 诱导的大鼠星形细胞瘤细胞系 (C6) 和小鼠小胶质细胞系(BV2) 中炎症因子释放失衡，抑制活性氧生成和亚硝酸盐释放。
Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NF-κB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure.
体内研究：
Perindopril erbumine (0.1 mg/kg，灌胃，一次一次，连续 5 天) 对 LPS 诱导的大鼠神经炎症具有保护作用。Perindopril erbumine (0.42 mg/kg ，口服，一次一次，连续 4 周) 联合黄芪丹参汤 (4.7 g/kg，口服，一次一次，连续 4 周) 减轻 adenine(HY-B0152) 诱导的大鼠慢性肾脏病 (CKD)。Perindopril erbumine (0.4-1.5 mg/kg，口服，每天 1 次，持续 4-24 周) 对自发性高血压大鼠 (SHR) 的血压有持续性影响。Animal Model:Adenine-induced chronic kidney disease rats
Dosage:0.1 mg/kg
Administration:Oral gavage (p.o.)
Result:Abolished the LPS-induced astroglial and microglial activation.Attenuated LPS-induced TNF-α production.Prevented LPS-induced nuclear translocation of NF-кB.Prevented the AT1R up-regulation and the LPS-induced decrease in the expression of PP2A.
Animal Model:Chronic kidney disease rats
Dosage:0.42 mg/kg
Administration:Oral
Result:Obviously reduced serum creatinine (Scr) and blood urea nitrogen (BUN) levels.Displayed a marked reduction of tubulointerstitial fibrosis.Exhibited more inhibitory effect on Col-IV expression and a exceed effect of raising OPA-1 expression.Significantly increased Sirtuin3 expression.Prevented mitochondrial fragmentation.
体外研究：
Perindopril erbumine (1 μM, 24 h) 改善 LPS (HY-D1056) 诱导的大鼠星形细胞瘤细胞系 (C6) 和小鼠小胶质细胞系(BV2) 中 AT2R 表达的减少和胶质增生。Perindopril erbumine (1 μM, 24 h) 抑制LPS (HY-D1056) 诱导的大鼠星形细胞瘤细胞系 (C6) 和小鼠小胶质细胞系(BV2)中 IκBα 降解，NF-кB 核转位和 STAT3 活化。Perindopril erbumine (1 μM, 24 h) 改善LPS (HY-D1056) 诱导的大鼠星形细胞瘤细胞系 (C6) 和小鼠小胶质细胞系(BV2) 中炎症因子释放失衡，抑制活性氧生成和亚硝酸盐释放。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备